Chemoradiotherapy with Integrated Boost Dose for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Small Cell Lung CancerChemoradiotherapy with Integrated Boost Dose - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a higher dose of radiation to areas of the tumor that are more active will reduce the rate of the cancer coming back in 2 years.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: 2 years

2 weeks
Dose Escalation Feasibility
2 years
Dose-Response Characterization
Grade 3-5 Toxicity Rate
Imaging Use
Overall Survival
Progression-Free Survival
Quality of Life EQ-5D
Quality of Life FACT-L
Reduction of local-regional failure rate

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Chemoradiotherapy
1 of 2
Chemoradiotherapy with Integrated Boost Dose
1 of 2

Active Control

Experimental Treatment

78 Total Participants · 2 Treatment Groups

Primary Treatment: Chemoradiotherapy with Integrated Boost Dose · No Placebo Group · N/A

Chemoradiotherapy with Integrated Boost Dose
Radiation
Experimental Group · 1 Intervention: Chemoradiotherapy with Integrated Boost Dose · Intervention Types: Radiation
Chemoradiotherapy
Radiation
ActiveComparator Group · 1 Intervention: Chemoradiotherapy · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
614 Previous Clinical Trials
402,093 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
are candidates for whole brain radiation therapy (WBRT) Patients with a tumor or node measuring at least 10mm on a CT scan are candidates for whole brain radiation therapy.
will be allowed to enroll People who are in good health and have a score of 0-2 on the Eastern Cooperative Oncology Group scale within 4 weeks of being randomized will be allowed to enroll in the study.
at our center Patients who will undergo radiation therapy as their primary mode of treatment at our center.
were found to have improved OS Patients with a PET avid tumor having Standardized Uptake Values (SUV) greater than 4 were found to have improved OS.